• Publications
  • Influence
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Although patients with advanced refractory solid tumors have poor prognosis, the clinical development of targeted protein kinase inhibitors offers hope for the future treatment of many cancers. InExpand
  • 1,108
  • 44
  • PDF
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.
Hepatocellular carcinoma (HCC) is a highly heterogeneous disease, and prior attempts to develop genomic-based classification for HCC have yielded highly divergent results, indicating difficulty inExpand
  • 687
  • 39
  • PDF
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.
Hepatocellular carcinomas represent the third leading cause of cancer-related deaths worldwide. The vast majority of cases arise in the context of chronic liver injury due to hepatitis B virus orExpand
  • 464
  • 23
  • PDF
Pivotal role of mTOR signaling in hepatocellular carcinoma.
BACKGROUND & AIMS The advent of targeted therapies in hepatocellular carcinoma (HCC) has underscored the importance of pathway characterization to identify novel molecular targets for treatment. WeExpand
  • 606
  • 22
Genomics and signaling pathways in hepatocellular carcinoma.
Hepatocellular carcinoma (HCC) is a leading cause of death among cirrhotic patients and has become a major health problem in developed countries. There is an elemental understanding of the genes andExpand
  • 505
  • 16
Experimental models of hepatocellular carcinoma.
Hepatocellular carcinoma (HCC) is a common and deadly cancer whose pathogenesis is incompletely understood. Comparative genomic studies from human HCC samples have classified HCCs into differentExpand
  • 187
  • 13
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.
BACKGROUND & AIMS In approximately 70% of patients with hepatocellular carcinoma (HCC) treated by resection or ablation, disease recurs within 5 years. Although gene expression signatures have beenExpand
  • 314
  • 8
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
BACKGROUND/AIMS The success of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) has focused interest on the role of Ras signaling in this malignancy. We investigated theExpand
  • 202
  • 4
Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy
The anecdotal reports of promising results seen with immunotherapy and radiation in advanced malignancies have prompted several trials combining immunotherapy and radiation. However, the ideal timingExpand
  • 135
  • 4
  • PDF
Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib
Purpose: Hepatocellular carcinoma (HCC) is a heterogeneous cancer with active Wnt signaling. Underlying biologic mechanisms remain unclear and no drug targeting this pathway has been approved toExpand
  • 112
  • 4